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Abstract
Background: The beneficial effects of statins in rheumatoid arthritis (RA) have been suggested previously, but it is unclear
whether statins may prevent its development. The aim of this retrospective cohort study was to explore whether persistent
use of statins is associated with onset of RA.
Methods and Findings: The computerized medical databases of a large health organization in Israel were used to identify
diagnosed RA cases among adults who began statin therapy between 1998 and 2007. Persistence with statins was assessed
by calculating the mean proportion of follow-up days covered (PDC) with statins for every study participant. To assess the
possible effects of healthy user bias, we also examined the risk of osteoarthritis (OA), a common degenerative joint disease
that is unlikely to be affected by use of statins. A total of 211,627 and 193,770 individuals were eligible for the RA and OA
cohort analyses, respectively. During the study follow-up period, there were 2,578 incident RA cases (3.07 per 1,000 person-
years) and 17,878 incident OA cases (24.34 per 1,000 person-years). The crude incidence density rate of RA among
nonpersistent patients (PDC level of ,20%) was 51% higher (3.89 per 1,000 person-years) compared to highly persistent
patients who were covered with statins for at least 80% of the follow-up period. After adjustment for potential confounders,
highly persistent patients had a hazard ratio of 0.58 (95% confidence interval 0.52–0.65) for RA compared with
nonpersistent patients. Larger differences were observed in younger patients and in patients initiating treatment with high
efficacy statins. In the OA cohort analysis, high persistence with statins was associated only with a modest decrement in risk
ratio (hazard ratio=0.85; 0.81–0.88) compared to nonadherent patients.
Conclusions: The present study demonstrates an association between persistence with statin therapy and reduced risk of
developing RA. The relationship between continuation of statin use and OA onset was weak and limited to patients with
short-term follow-up.
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Rheumatoid arthritis (RA) is a leading cause of disability that
often reduces patients’ quality of life and impairs their ability to
work [1]. Prevalence estimates of RA worldwide indicate that the
prevalence of RA range between 2.0 to 10.7 per 1,000 adults,
based on the 1987 revised American College of Rheumatology
(ACR) criteria [2].
RA is a chronic systemic inflammatory condition characterized
by leukocyte recruitment into synovial tissue. There is growing
evidence that statins have anti-inflammatory and immunumodu-
latory properties, demonstrated by reducing the level of C-reactive
protein (CRP) that may play an important role in RA,
independent of their cholesterol lowering effects [3,4]. A modest
beneficial effect of statins in RA has been demonstrated by several
small randomized clinical trials and observational studies that
reported on decreased disease activity [5,6], decreased CRP levels,
reduced number of swollen joints [6,7], and improved vascular
function [8,9]. In contrast, a large US medical and pharmacy
claims study [10] showed no beneficial effect for statins among
31,451 RA patients as measured by initiation and cessation of oral
steroids. Consequently, there is a need for large investigations with
long follow-up periods to explore whether statins can be shown not
only to improve the clinical manifestation of RA, but perhaps also
to relate to lower RA occurrence. In our previous studies we
examined the effect of persistent use of statins on all-cause
mortality [11], incident cataract [12], and age-related macular
degeneration. In the present study, we evaluated the association
between persistence with statins and onset of RA among a large,
unselected population of statin users who were at least 18 y of age
and did not have RA or a related disease, including symptomatic
osteoarthritis (OA) or rheumatic fever, at study entry.
Methods
Study Population
We conducted a retrospective cohort study among the members
of Maccabi Healthcare Services (MHS), a 1.8-million enrollee
health maintenance organization (HMO) operating in Israel.
According to the Israeli National Health Insurance Act, MHS may
not bar any citizen who wishes to join it, and therefore every
section in the Israeli population is represented in MHS. According
to the most recent report of the Israel National Insurance [13], the
mean age and proportion of women among MHS members
(31.0 y, 48.6%) is similar to the general population (32.4 y,
48.9%). All data were obtained from MHS automated databases
that have previously been described [11] and were used to elicit
information on all dispensed community prescriptions, hospital
discharge data, biochemistry results, using a unique nine-digit
national identification number. Research ethics approval was
obtained from Assuta Medical Center institutional review
board.
Study Outcome
Incident cases of RA were defined by the date of first diagnostic
codes associated with RA (Rheumatoid arthritis; International
Classification of Diseases, 9th revision [ICD-9] codes 714.x)
during the study follow-up period. The tendency of healthier
patients to be more likely to persist with preventive treatments
leads to a bias that has been termed ‘‘healthy user bias’’ [14]. To
assess the potential effects of this possibly important bias, we also
examined the association between persistence with statins and OA
(Osteoarthritis; ICD-9 codes 715.x), a common degenerative joint
disease that is unlikely to be affected by statin use.
Cohort Definition
The cohort covered the period 1998–2007 and included
members who were continuously enrolled in the HMO from
1995 to 1998. New users of statins were identified among all MHS
enrollees aged 18 y or older, who from January 1, 1998 to July 1,
2007 had at least one dispensed prescription of 3-hydroxy-3-
methylgluraryl coenzyme A (HMG-CoA) reductase inhibitors
(e.g., lovastatin, pravastatin, simvastatin, atorvastatin). The date of
first purchased statin was defined as the index date. We only
included patients who were enrolled in MHS and did not have a
statin prescription at least 3 y prior to the index date. Also
excluded were patients who had been diagnosed with RA, OA, or
rheumatic fever, and patients who had any dispensed relevant
medications (methotrexate, sulphasalzine, prednisone, lefluno-
mide, azathioprine, infliximab, etanercept, adalimumab, hydroxy-
chloroquine, auranofin, rituximab [abatecept is currently not
available in Israel]) prior to the index date or within 1 y after the
index date.
Proportion of Days Covered
Following previous studies [15–17], we calculated the mean
proportion of days covered (PDC) by dividing the quantity of
statins dispensed by the total time interval from index date to first
diagnosis of RA or OA, death, leaving MHS, or December 31,
2007, whichever occurred first.
Other Study Variables
Demographic variables at index date included baseline values of
age, gender, marital status, place of residency, years of stay in Israel
(for new immigrants). Socioeconomic level was categorized into
quintiles according to the poverty index of the member’s
enumeration area, as defined by 1995 national census. The poverty
index is based on several parameters including, household income,
educational qualifications, crowding, material conditions, and car
ownership [18]. Study subjects’ electronic medical records were
reviewed for a diagnosis of chronic conditions defined by ICD-9
codes. Diabetes mellitus patients were identified by using the MHS
computerized diabetes mellitus patient registry [19]. Informationon
cancer history was provided by the Israel National Cancer Registry
(INCR), which has collected information of diagnosed cancer cases
from all medical institutions in Israel since 1960.
Information on health services utilization, such as number of
hospitalizations in general hospitals, visits to outpatient clinics, and
filled prescriptions of antihypertensive drugs and diuretics, was
based on data collected for the year prior to the index date.
Laboratory test results included liver function and the median of
all low-density lipoprotein (LDL)-cholesterol tests during the year
prior to the index date, as well as presence of rheumatoid factor
(RF) in patients diagnosed with RA.
Lipid-Lowering Pharmacotherapy
On the basis of previous clinical trials [20–24], statin therapy
was categorized into three relative efficacy levels that were created
from expected amounts of LDL-cholesterol reduction from
baseline: (a) low efficacy (#30% LDL reduction): daily dose of
fluvastatin #40 mg, pravastatin #40 mg, simvastatin #10 mg,
cerivastatin 0.2 mg, or lovastatin #40 mg or 10 mg twice daily; (b)
moderate efficacy (31%–40% LDL reduction): daily dose of
fluvastatin 80 mg, cerivastatin 0.3 mg or 0.4 mg, rosuvastatin
,10 mg, simvastatin 20 mg or 40 mg, atorvastatin 10 mg; or (c)
high efficacy ($41% LDL reduction): simvastatin 80 mg,
atorvastatin $20 mg, rosuvastatin $10 mg, pravastatin 80 mg,
or lovastatin 80 mg).
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Patient Characteristics
at Index Date Substrata Proportion of Follow-up Period Covered with Statins p-Value
a
,20% 20%–39% 40%–59% 60%–79% $80% Total
n=57,690 n=30,025 n=30,542 n=37,451 n=55,919 n=211,627
Age (y) Mean 53.55 56.52 57.70 58.51 60.07 57.17 ,0.001
(SD) (15.13) (12.29) (11.82) (11.50) (11.09) (12.89)
Sex Men 27,255 14,398 14,674 18,617 28,904 103,848 ,0.001
Percent 47.3 48.0 48.1 49.7 51.7 49.1
Socioeconomic level Mean 9.99 9.44 9.70 10.09 10.72 10.08 ,0.001
(SD) (5.63) (5.73) (5.92) (6.02) (6.09) (5.90)
LDL-cholesterol (mg/dl)
b ,130 11,956 4,181 4,101 5,066 8,682 33,986 ,0.001
Percent 20.7 13.9 13.4 13.5 15.5 16.1
130–159 14,674 8,203 8,285 10,287 16,225 57,674
Percent 25.4 27.3 27.1 27.5 29.0 27.3
160–189 15,123 9,769 10,061 12,230 17,319 64,502
Percent 26.2 32.5 32.9 32.7 31.0 30.5
$190 7,967 5,562 5,759 6,995 8,683 34,966
Percent 13.8 18.5 18.9 18.7 15.5 16.5
Missing data 7,970 2,310 2,336 2,873 5,010 20,499
Percent 13.8 7.7 7.6 7.7 9.0 9.7
Comorbid conditions Obesity 9,055 5,548 5,358 6,347 9,213 35,521 ,0.001
Percent 15.7 18.5 17.5 16.9 16.5 16.8 ,0.001
Cancer 4,399 2,357 2,658 3,470 5,703 18,587 ,0.001
Percent 7.6 7.9 8.7 9.3 10.2 8.8
DM 10,167 8,403 8,987 11,341 17,985 56,883
Percent 17.6 28.0 29.4 30.3 32.2 26.9
CVD 17,125 10,519 12,085 16,572 28,268 84,569
Percent 29.7 35.0 39.6 44.2 50.6 40.0
n Hospitalizations
b None 50,881 26,352 26,682 32,713 47,886 184,514 ,0.001
Percent 88.2 87.8 87.4 87.3 85.6 87.2
1 4,848 2,559 2,711 3,273 5,383 18,774
Percent 8.4 8.5 8.9 8.7 9.6 8.9
2 or more 1,961 1,114 1,149 1,465 2,650 8,339
Percent 3.4 3.7 3.8 3.9 4.7 3.9
n GP visits quintiles
b #7 15,220 6,945 6,412 7,584 10,003 46,164 ,0.001
Percent 26.6 23.2 21.1 20.3 18.0 21.9
8–12 12,064 6,090 6,034 7,065 9,636 40,889
Percent 21.1 20.4 19.8 18.9 17.3 19.4
13–19 11,989 6,548 6,668 8,268 12,298 45,771
Percent 21.0 21.9 21.9 22.1 22.1 21.7
20–29 9,244 5,300 5,794 7,257 11,570 39,165
Percent 16.2 17.7 19.1 19.4 20.8 18.6
30# 8,678 5,012 5,502 7,159 12,204 38,555
Percent 15.2 16.8 18.1 19.2 21.9 18.3
Statin efficacy Low 22,037 9,778 10,733 13,910 22,827 79,285 ,0.001
Percent 38.2 32.6 35.1 37.1 40.8 37.5
Moderate 33,819 18,341 17,503 20,620 29,377 119,660
Percent 58.6 61.1 57.3 55.1 52.5 56.6
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A chi-square test for categorical variables and a Kruskal-Wallis
test for continuous variables were performed to determine
significant differences in baseline characteristics and levels of
PDC with statins that were categorized into ,20% (reference
category), 20%–39%, 40%–59%, 60%–79%, and 80% or above.
In the primary analysis, a Cox proportional hazards model with
years of follow-up as the time scale was used to estimate hazard
ratios (HRs) and 95% confidence intervals (CIs) [25] and to
identify variables significantly associated with increased risk of RA.
In the secondary analysis, similar regression models were
computed with OA as a dependent variable. In both analyses,
each participant was followed from the first purchase of statin to
first diagnosis of RA (or OA), leaving MHS, or December 31,
2007, whichever occurred first. The maximum follow-up was
approximately 10 y. To examine a potential prevalence incidence
bias, we excluded patients with less than 1 y of follow-up. In
addition, we conducted sensitivity analyses limited to patients with
at least 5 y of follow-up.
The full multivariate model included the following baseline
values: age at baseline (in 1-y intervals), gender, marital status,
nationality, socioeconomic level, presence of chronic comorbidity,
utilization of health services, LDL cholesterol level, and efficacy of
the initial statin therapy. Tests for trend of ordinal variables were
based on the category median values. Analyses were stratified by
age categories, sex, baseline LDL levels, and efficacy of initial
statin therapy. A chi-square test was performed to assess
heterogeneity.
Results
The median number of health plan enrollees during the study
period was more than 1.6 million, with persons aged 18 y or above
accounting for 66% of the population. After applying the inclusion
and exclusion criteria, a total of 211,627 individuals for the RA
analysis and 193,770 individuals for the OA analysis were
identified as being newly treated with statin agents during the
study period. During the study follow-up period 11,692 individuals
died and 3,343 left MHS.
Baseline characteristics of the study population eligible for the
RA analysis cohort and for the OA analysis are given in Tables 1
and 2, respectively. Patients with high PDC were more likely to be
older, belong to a lower socioeconomic level, have higher
prevalence of chronic conditions such as cancer, diabetes, and
cardiovascular diseases, and have more frequent hospitalizations
and visits to primary physicians. During 4.97 and 4.79 y of mean
follow-up in the RA and OA analyses, there were 2,578 (3.07 per
1,000 person-years) RA cases and 17,878 OA cases (24.34 per
1,000 person-years), respectively. The age- and sex-specific
incidence rates of RA and OA in the study population during
the 10 y of study period are depicted in Figure 1. In most age
groups, the incidence rate of RA and OA was 2- to 3-fold higher in
women compared to men, and increased with age to a maximum
in women aged 65–74 y (4.78 for RA and 50.45 per 1,000 for
OA). RF tests were available for 76.6% of the diagnosed RA cases,
of whom 1,478 (76.0%) were positive for RF at $10 IU/ml and
714 (36.7%) were positive for RF at $40 IU/ml.
The crude incidence density rate of RA among patients with a
PDC level of less than 20% (3.89 per 1,000 [95% CI 3.62–4.17])
was higher by 51% compared to patients with a PDC level of 80%
(2.57 per 1,000 [2.37–2.78]). No similar pattern was observed in
the OA analysis where the incidence density rate of OA in the
lowest PDC level category (23.61 per 1,000: 95% CI 22.92–24.31)
was comparable to the incidence in the highest PDC level (24.12
per 1,000) (Table 3).
Baseline characteristics associated with increased risk for RA
and OA included age, female gender, and frequent visits to
primary physicians (Tables 4 and 5). Morbid obesity was related to
a substantially higher risk of OA (HR=1.72; 95% CI 1.65–1.78),
but not to RA. Similar results were obtained when analyses were
limited to patients with at least 5 y of follow-up.
After adjustment for the variables in Table 4, patients with a
PDC with statins of 80% or above, had a HR of 0.58 (95% CI
0.52–0.65) for RA compared with patients with PDC levels of less
than 20% (Table 4). Similar results were obtained when analyses
were restricted to patients with $5 y of follow-up. In the OA
cohort analysis (Table 5), high persistence with statins (PDC level
$80%) was associated only with a modest decrement in risk ratio
(HR=0.85; 0.81–0.88) compared to nonadherent patients (PDC
level ,20%). In contrast with the RA analysis, the negative
association between OA risk and PDC with statins was not
observed when analyses were limited to patients with at least 5 y of
follow-up (Figure 2).
When PDC with statins was analyzed as a continuous variable,
an increase of 10% in PDC level was associated with an adjusted
HR of 0.95 (95% CI 0.94–0.96) or a 5.3% lower risk of RA.
Similar results were obtained when analyses were limited to
patients with $5 y of follow-up. In the OA analysis, a 10%
increase in PDC was related with an adjusted HR of 0.99 (95% CI
0.99–1.00) for OA. No association (p=0.23) was calculated when
analyses were limited to patients with $5 y of follow-up. In
stratified analyses, younger age at index date was associated with
larger differences in RA risk. In patients aged 35–44 y, an increase
of 10% in days covered with statins was associated with an
adjusted HR of 0.90 (95% CI 0.87–0.97), whereas in patients aged
75 y or above, there was no significant association between
Patient Characteristics
at Index Date Substrata Proportion of Follow-up Period Covered with Statins p-Value
a
,20% 20%–39% 40%–59% 60%–79% $80% Total
n=57,690 n=30,025 n=30,542 n=37,451 n=55,919 n=211,627
High 1,828 1,904 2,300 2,917 3,703 12,652
Percent 3.2 6.3 7.5 7.8 6.6 6.0
aKruskal-Wallis test for continuous data; x
2 test for categorical data.
bIn the year prior to Index date.
GP, general practitioner; SD, standard deviation.
doi:10.1371/journal.pmed.1000336.t001
Table 1. Cont.
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Patient Characteristics
at Index Date Substrata Proportion of Follow-up Period Covered with Statins p-Value
a
,20% 20%–39% 40%–59% 60%–79% $80% Total
n=54,378 n=27,358 n=27,794 n=34,001 n=50,239 n=193,770
Age (y) Mean 52.81 55.77 57.04 57.86 59.41 56.43 ,0.001
(SD) (15.02) (12.20) (11.76) (11.46) (11.08) (12.87)
Sex Men 26,290 13,612 13,941 17,610 27,185 98,638 ,0.001
Percent 48.4 49.8 50.2 51.8 54.1 50.9
Socioeconomic level Mean (SD) 10.12 (5.59) 9.65 (5.70) 9.92 (5.90) 10.28 (5.99) 10.91 (6.04) 10.26 (5.86) ,0.001
LDL-cholesterol
b (mg/dl) ,130 7,785 2,184 2,202 2,746 4,717 19,634 ,0.001
Percent 14.3 8.0 7.9 8.1 9.4 10.1
130–159 11,062 3,708 3,691 4,561 7,728 30,750
Percent 20.3 13.6 13.3 13.4 15.4 15.9
160–189 13,553 7,310 7,367 9,150 14,314 51,694
Percent 24.9 26.7 26.5 26.9 28.5 26.7
$190 14,305 8,934 9,143 11,062 15,533 58,977
Percent 26.3 32.7 32.9 32.5 30.9 30.4
Missing data 7,673 5,222 5,391 6,482 7,947 32,715
Percent 14.1 19.1 19.4 19.1 15.8 16.9
Comorbid conditions Obesity 8,376 4,885 4,681 5,525 7,861 31,328 ,0.001
Percent 15.4 17.9 16.8 16.2 15.6 16.2 ,0.001
Cancer 4,038 2,095 2,404 3,092 5,070 16,699 ,0.001
Percent 7.4 7.7 8.6 9.1 10.1 8.6
DM 9,579 7,547 8,134 10,160 16,021 51,441
Percent 17.6 27.6 29.3 29.9 31.9 26.5
CVD 16,040 9,585 11,074 15,047 25,514 77,260
Percent 29.5 35.0 39.8 44.3 50.8 39.9
n Hospitalizations
b None 48,080 24,076 24,319 29,722 43,039 169,236 ,0.001
Percent 88.4 88.0 87.5 87.4 85.7 87.3
1 4,494 2,268 2,446 2,943 4,780 16,931
Percent 8.3 8.3 8.8 8.7 9.5 8.7
2 or more 1,804 1,014 1,029 1,336 2,420 7,603
Percent 3.3 3.7 3.7 3.9 4.8 3.9
n GP
b visits (quintiles) Lowest
(#7 visits)
14,909 6,656 6,177 7,284 9,514 44,540 ,0.001
Percent 27.7 24.4 22.3 21.5 19.0 23.1
2nd (8–12 visits) 11,648 5,775 5,635 6,724 9,078 38,860
Percent 21.6 21.2 20.4 19.8 18.1 20.2
3rd
(13–19 visits)
11,348 6,020 6,164 7,615 11,309 42,456
Percent 21.1 22.1 22.3 22.5 22.6 22.0
4th
(20–29 visits)
8,511 4,671 5,196 6,451 10,215 35,044
Percent 15.8 17.2 18.8 19.0 20.4 18.2
Highest
($30 visits)
7,474 4,108 4,490 5,813 9,918 31,803
Percent 13.9 15.1 16.2 17.2 19.8 16.5
Statin efficacy Low 20,712 8,886 9,730 12,575 20,484 72,387 ,0.001
Percent 38.3 32.7 35.2 37.2 41.0 37.6
Moderate 31,498 16,528 15,738 18,517 26,029 108,310
Percent 58.3 60.8 56.9 54.8 52.1 56.2
High 1,804 1,763 2,175 2,709 3,450 11,901
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heterogeneity test between all age strata did not reach statistical
significance. Similarly, substantially lower risk of RA was
calculated for patients persistently treated with high efficacy
statins with a statistically significant heterogeneity (Figure 3).
Discussion
The present study demonstrates a significant negative associa-
tion between persistence with statin therapy and RA onset,
particularly in adult patients who began treatment at a relatively
young age and with high efficacy statins. Our results agree with a
previous nested case-control study [26] in hyperlipidemia patients,
which compared 313 RA patients and 1,252 matched controls. In
that analysis, the adjusted OR for development of RA in subjects
taking statins compared to the reference group was 0.59 (95% CI
0.37–0.96). Similar to the present study, it was also found that
patients receiving high efficacy statins (atorvastatin) had a lower
odds ratio for contracting RA, although the difference did not
reach statistical significance.
Several of the cholesterol-independent effects of statins are
exerted by the modulation of the synthesis of isoprenoids. Post-
translational modification by isoprenylation is inhibited by statins;
statins decrease isoprenylation of the GTP-binding proteins Ras
and Rho, which consequently leads to the modulation of signaling
pathways involving endothelial nitric oxide synthase [27], tissue
plasminogen activator [28], endothelin 1 [29], plasminogen
activator inhibitor 1 [30], and CRP [31]. Statins were also shown
to effectively suppress the induction of class II major histocom-
patibility complex (MHC) protein and gene expression by
interferon-c (IFNc), resulting in suppressed class II MHC-
mediated T cell activation [32]. Interestingly, statins also
selectively block b2 integrin and lymphocyte function-associated
antigen 1 (LFA-1). In addition LFA-1 binding to intercellular
adhesion molecule 1 (ICAM-1) was also abrogated by statins
[33].
Patient Characteristics
at Index Date Substrata Proportion of Follow-up Period Covered with Statins p-Value
a
,20% 20%–39% 40%–59% 60%–79% $80% Total
n=54,378 n=27,358 n=27,794 n=34,001 n=50,239 n=193,770
Percent 3.3 6.5 7.9 8.0 6.9 6.2
aKruskal-Wallis test for continuous data; x
2 test for categorical data.
bIn the year prior to Index date.
CVD, cardiovascular disease; DM, diabetes mellitus; GP, general practitioner; SD, standard deviation.
doi:10.1371/journal.pmed.1000336.t002
Table 2. Cont.
Figure 1. Incidence density rate (per 1,000 person-years) of RA and OA in study cohort, by age and sex, 1998–2006.
doi:10.1371/journal.pmed.1000336.g001
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tatin altered cytokine secretion favoring Th2 cytokine (interleukin
[IL]-4, IL-5, IL-10, and transforming growth factor b) secretion
while inhibiting the expression of Th1 cytokines (IL-2, IL-12,
IFNc, and tumor necrosis factor a [TNFa]). Interestingly, CD40
signaling, which is implicated in the pathogenesis of many
autoimmune conditions, was reduced by statins in atheroma-
associated cells in vitro and in atherosclerotic lesions; this change
hinders proinflammatory cytokines, chemokines, matrix metallo-
proteinases, and tissue factor secretion and activity [34].
Additional features of statins are bone-specific anabolic and
antiresorptive effects that may prevent osteoporosis, which often
occurs in patients with active RA. These mechanisms may
elucidate the improved, yet modest overall, RA disease activity,
swollen joint scores, and reduced CRP in the TARA (Trial of
Atorvastatin in Rheumatoid Arthritis) trial, a 6-mo, placebo-
controlled, randomized clinical trial with Atorvastatin [6].
The JUPITER (Justification for the Use of Statins in Prevention:
an Intervention Trial Evaluating Rosuvastatin) trial was designed to
investigate the preventive effects of Rosuvastatin against vascular
events among individuals with LDL cholesterol ,130 mg/dl and
enhanced innate immune response, as determined by a high-
sensitivity CRP (hsCRP) level. The results of the JUPITER trial
indicated that statin therapy may also reduce all cause mortality in
patients with low LDL cholesterol, probably by decreased
inflammation [35]. Although RA patients were not included in
the JUPITER trial, the questionable validity of its conclusions [36],
and the uncertainty of whether or not CRP itself is a marker of risk
or the target for therapy, our findings may support the potential
relationship between statin use and RA risk [37].
The strengths of the current study include prospective data
collection, the use of administrative databases to avoid the
problem of differential recall bias, the systematic and comprehen-
sive collection of personal sociodemographic data, medical history,
and utilization of health services prior to the index date, which
reduces the possibility for bias due to study outcomes. The present
retrospective cohort is one of the largest undertaken to date on the
relationship between statin therapy and RA, with respect to the
length of follow-up and the size of the study population.
Furthermore, survivor-treatment selection bias and competing
medical issues, two potential problems with observational studies
of treatment efficacy [38], are unlikely to affect our results, since
the association of statins and RA onset was not attenuated when
analyses were limited only to patients with more than 5 y of follow-
up data.
In addition, the present study used internal comparisons among
patients who had at least one dispensed prescription of statins,
reducing the threat of confounding by indication that might have
occurred in previous investigations that compared statin users and
nonusers [26]. For example, a recently published cohort study [39]
on more than 2 million patients from 368 general practices in
England and Wales found no significant association between statin
use and RA. In their analysis, Hippisley-Cox and Coupland
compared the risk of RA in statin users and nonusers. The study
groups differed considerably in many important characteristics such
as mean age (57 versus 44 y), body mass index (BMI) (28.3 versus
26), and potentially in other important variables that were not
included in the multivariable analysis (e.g., cholesterol level, LDL
levels, cardiovascular diseases, and other comorbid conditions, etc.).
Inaddition,the authors reduced the statisticalpowerof theirtestsby
stratifying the analyses by sex and five types of statins, and did not
take into account the effect of time and amount of statin purchased.
All of the above mentioned aspects could have masked a significant
association between persistent use of statins and RA.
This study has the following limitations. Our analysis was
retrospective in nature and allocation of statin therapy was not
randomized. Despite adjustment for baseline differences and an
abundance of poor prognostic factors, a higher proportion of days
covered with statins could still be a surrogate for other unmeasured
variables that reflect a higher quality of care and more aggressive
treatment strategies. In our analysis we did not address different
temporal variations in patients’ use of statins over the study period.
However, a majority of RA patients (79%) purchased statins at
least 3 mo prior to diagnosis. Also, the similarity in study results
when limiting the analysis to patients with at least 5 y of follow-up
reduces the possible effect of this potential limitation.
Table 3. Incidence density rates (IDR) of RA and OA according to the PDC with statins, MHS 1998–2007.
PDC with Statins Follow-up Mean (SD) Person-Years at Risk
a n Cases IDR per 1,000 95% CI
RA analysis
,20% (n=57,690) 4.55 (2.46) 204732 796 3.89 3.62–4.17
20%–39% (n=30,025) 4.82 (2.66) 114822 356 3.10 2.79–3.44
40%–59% (n=30,542) 5.12 (2.69) 125806 403 3.20 2.90–3.53
60%–79% (n=37,451) 5.21 (2.76) 157550 411 2.61 2.36–2.87
$80% (n=55,919) 5.26 (2.83) 238157 612 2.57 2.37–2.78
Total (n=211,627) 4.97 (2.69) 841067 2578 3.07 2.95–3.19
OA analysis
,20% (n=54,378) 4.42 (2.42) 186120 4394 23.61 22.92–24.31
20%–39% (n=27,358) 4.64 (2.61) 99457 2501 25.15 24.18–26.14
40%–59% (n=27,794) 4.93 (2.65) 109269 2663 24.37 23.46–25.30
60%–79% (n=34,001) 4.99 (2.71) 135512 3395 25.05 24.23–25.90
$80% (n=50,239) 5.06 (2.78) 204173 4925 24.12 23.46–24.80
Total (n=193,770) 4.79 (2.64) 734531 17878 24.34 23.99–24.69
aExcluding first year of follow-up.
SD, standard deviation.
doi:10.1371/journal.pmed.1000336.t003
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effectiveness in observational studies is the potential for ‘‘healthy
adherer’’ bias. Previous studies have indicated that in patients with
a chronic illness, good adherence to medication, or even to
placebo, is more likely to lead to better health and improved
survival [40]. A recent study [41] aimed to examine whether
adherence with statins is associated with a decreased risk of
accidental events that were thought to be unrelated to statins (e.g.,
motor vehicle and workplace accidents, burns, and falls). As
expected, they found a modest (10%–15%) overall reduction in
accident rate among adherent patients compared to nonadherent
ones. In order to evaluate this potentially important bias in our
study, we conducted a similar analysis with OA as an outcome.
Our results indicated that persistent use of statins was associated
with a 15% lower OA risk, a relatively small difference compared
to RA risk, but one that needs to be noted when considering the
results of the study overall. In addition, the reduced risk for OA in
patients with high PDC with statins was limited to patients with
short follow-up periods and was not found in patients with a
follow-up of 5 y or more. This finding supports the notion that
most of the RA risk reduction is due to a real biological effect. The
threat of ‘‘healthy adherer bias’’ in this study was further
diminished by findings from our previous study [42] on the
present cohort indicating that older age and the presence of
chronic diseases and other risk factors for cardiovascular events are
associated with higher persistence with statins.
The incidence of RA and OA in our study, based on physician
diagnoses, is higher compared with previous studies [2,43,44].
Table 4. Mutually adjusted HRs and 95% CIs for RA according to PDC with statins and baseline characteristics, MHS 1998–2007.
Factors Associated with RA Onset .1 y of Follow-up (2,375 Cases) .5 y of Follow-up (892 Cases)
HR 95% CI p-Value
a HR 95% CI p-Value
a
Age (per 1 y) 1.01 1.01–1.01 ,0.001 1.01 1.01–1.02 ,0.001
Sex (women vs. men) 1.95 1.78–2.13 ,0.001 1.91 1.65–2.22 ,0.001
Socioeconomic level 1.01 1.01–1.02 ,0.001 1.02 1.01–1.03 0.001
n GP visits quintile
b
#7 1 (ref.) 1 (ref.)
8–12 0.95 0.81–1.11 0.510 0.91 0.70–1.18 0.477
13–19 1.19 1.04–1.38 0.015 1.27 1.00–1.61 0.046
20–29 1.41 1.22–1.62 ,0.001 1.34 1.05–1.70 0.018
30+ 1.98 1.72–2.27 ,0.001 1.97 1.56–2.49 ,0.001
n Hospitalizations
b
None 1 (ref.) 1 (ref.)
1 0.88 0.76–1.02 0.086 0.93 0.74–1.16 0.518
2+ 0.85 0.69–1.05 0.133 0.84 0.60–1.19 0.327
Chronic conditions:
CVD (yes vs. no) 0.96 0.88–1.05 0.364 1.00 0.87–1.16 0.981
Morbid obesity (yes vs. no) 1.02 0.91–1.14 0.753 1.12 0.94–1.34 0.201
Cancer (yes vs. no) 0.89 0.78–1.02 0.093 0.98 0.79–1.20 0.821
Diabetes (yes vs. no) 1.02 0.93–1.11 0.737 1.03 0.89–1.19 0.683
LDL level
b (mg/dl)
,130 1 (ref.) 1 (ref.)
130–159 0.94 0.83–1.06 0.323 0.96 0.78–1.18 0.700
160–189 0.96 0.85–1.09 0.523 0.97 0.79–1.18 0.744
190+ 0.84 0.72–.97 0.014 0.97 0.77–1.21 0.765
Statin efficacy
Low 1 (ref.) 1 (ref.)
Moderate 1.08 0.99–1.18 0.082 0.96 0.83–1.11 0.606
High 1.13 0.95–1.33 0.161 1.14 0.89–1.45 0.292
PDC with statins
,20% 1 (ref.) 1 (ref.)
20%–39% 0.74 0.65–0.85 ,0.001 0.75 0.60–0.94 0.014
40%–59% 0.77 0.68–0.88 ,0.001 0.75 0.60–0.93 0.01
60%–79% 0.61 0.54–0.69 ,0.001 0.69 0.56–0.85 ,0.001
$80% 0.58 0.52–0.65 ,0.001 0.69 0.57–0.83 ,0.001
aKruskal-Wallis test for continuous data; x
2 test for categorical data.
bIn the year prior to Index date.
CVD, cardiovascular disease; GP, general practitioner.
doi:10.1371/journal.pmed.1000336.t004
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and the frequent visits to physicians in our study population,
leading to earlier detection. Also, RA cases in most epidemiolog-
ical studies were defined by the 1987 ACR criteria and not on
diagnosis alone as in our study. The association between LDL
levels and risk of RA is not fully understood. Some studies [45–47],
but not all [48], suggested that patients with active untreated RA
have reduced LDL levels. A recent large retrospective cohort from
the Rochester Epidemiology Project showed a decrement in LDL
levels during the 5-y period before RA incidence. This decrement
could not be explained by usage of lipid-lowering drugs alone.
This conclusion is in agreement with our finding that high LDL
levels (.190 mg/dl) at index date were significantly associated
with a lower short-term (,5 y) risk of RA. Since patients with
higher LDL levels at index date are more likely to be persistent
with statin therapy [49], a residual confounding cannot be
excluded.
Mild muscle pains are one of the frequent side effects of statins
documented in 5% to 10% of outpatients on statins [50,51] and
commonly result in discontinuation of treatment. Muscle symp-
toms frequently begin within several months after initiation of
therapy [50]. Since muscle pains can be misclassified as OA
symptoms and result in result in a mistaken diagnosis of OA
shortly after treatment initiation. This potential differential
information bias may explain the disappearance of the small
negative association between statin use and OA when analysis was
limited to patients with at least 5 y of follow-up. Also, one might
claim that persistent use of statins may have been associated with
Table 5. Mutually adjusted HRs and 95% CIs for OA according to PDC with statins and baseline characteristics, MHS 1998–2007.
Factors associated with OA Onset .1 y of Follow-up (16,595 Cases) .5 y of Follow-up (5,285 Cases)
HR 95% CI p-Value
a HR 95% CI p-Value
a
Age (per 1 y) 1.03 1.03 1.03 ,0.001 1.03 1.02 1.03 ,0.001
Sex (women vs. men) 1.81 1.75 1.88 ,0.001 1.78 1.68 1.89 ,0.001
Socioeconomic level 0.98 0.98 0.98 ,0.001 0.98 0.98 0.99 ,0.001
n GP visits
b
#7 1 (ref.) 1 (ref.)
8–12 1.08 1.02 1.15 0.006 1.10 0.99 1.22 0.079
13–19 1.24 1.18 1.31 ,0.001 1.30 1.18 1.44 ,0.001
20–29 1.56 1.48 1.65 ,0.001 1.58 1.44 1.74 ,0.001
30# 1.95 1.85 2.06 ,0.001 1.91 1.73 2.11 ,0.001
n Hospitalizations
b
None 1 (ref.) 1 (ref.)
1 0.90 0.85 0.95 ,0.001 0.88 0.80 0.97 0.008
2+ 0.79 0.73 0.86 ,0.001 0.83 0.72 0.95 0.007
Chronic conditions:
CVD (yes vs. no) 0.91 0.88 0.94 ,0.001 0.96 0.90 1.01 0.143
Morbid obesity (yes vs. no) 1.72 1.65 1.78 ,0.001 1.75 1.64 1.88 ,0.001
Cancer (yes vs. no) 0.94 0.89 0.98 0.007 0.97 0.89 1.05 0.448
Diabetes (yes vs. no) 0.97 0.94 1.01 0.139 0.95 0.90 1.01 0.094
LDL level
b (mg/dl)
,130 1 (ref.) 1 (ref.)
130–159 1.04 0.99 1.09 0.123 1.04 0.96 1.13 0.351
160–189 1.01 0.96 1.06 0.672 0.98 0.90 1.07 0.689
190+ 0.95 0.90 1.00 0.075 1.04 0.95 1.14 0.443
Statin efficacy
Low 1 (ref.) 1 (ref.)
Moderate 1.05 1.02 1.09 0.002 1.05 0.98 1.11 0.148
High 1.14 1.08 1.21 ,0.001 1.07 0.97 1.18 0.196
PDC with statins
,20% 1 (ref.) 1 (ref.)
20%–39% 0.93 0.88 0.98 0.005 1.08 0.98 1.19 0.113
40%–59% 0.87 0.83 0.92 ,0.001 1.01 0.92 1.12 0.775
60%–79% 0.89 0.85 0.93 ,0.001 1.10 1.01 1.20 0.037
$80% 0.85 0.81 0.88 ,0.001 1.06 0.97 1.15 0.188
aKruskal-Wallis test for continuous data; x
2 test for categorical data.
bIn the year prior to Index date.
CVD, cardiovascular disease; GP, general practitioner.
doi:10.1371/journal.pmed.1000336.t005
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PLoS Medicine | www.plosmedicine.org 9 September 2010 | Volume 7 | Issue 9 | e1000336Figure 2. Adjusted HR and 95% CI for RA and OA, according to PDC with statins in patients with at least 5 y of follow-up. Adjusted
for baseline values of age, sex, socioeconomic level, utilization of healthcare services in the year prior to index date, chronic comorbidity
(cardiovascular diseases, diabetes mellitus, cancer, morbid obesity), LDL level, and statin efficacy.
doi:10.1371/journal.pmed.1000336.g002
Figure 3. Proportional effects of persistence with statins on reduction of risk for RA per 10% of follow-up days covered with statins.
Squares indicate adjusted HRs, horizontal lines, 95% CIs. Mutually adjusted for all covariates listed in Table 4.
doi:10.1371/journal.pmed.1000336.g003
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diagnosed with RA or OA. However, the direction of this potential
detection bias may only support our conclusions. In the present
research, not only did the risk of RA not rise with increasing
persistence, it decreased, indicating that the true association
between persistent statin use and RA could be stronger than
observed. Interestingly, starting statin treatment at a younger age
(35–44 y) was associated with a more pronounced decline of onset
of RA; this finding probably underlines the importance of
inflammatory processes during this age and the potential role
statins may have to block these mechanisms, in other words, the
different effects that statins have at different ages once again
implies that RA is a heterogeneous disease.
In conclusion, this study showed that persistence with statin
treatment was associated with an ongoing decrement in the risk for
contracting RA. The observed associations were greater than those
that would be expected from methodological biases alone. Larger,
systematic, controlled, prospective studies with high efficacy
statins, particularly in younger adults who are at increased risk
for RA, are needed to confirm our findings, and to elucidate the
possible biological relationship between adherence to statin
therapy and RA onset.
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Background T h er o l eo fs t a t i n si nt h em anagement of diseases
that have an inflammatory component is unclear. There is
some evidence that statins may have anti-inflammatory and
immunumodulatory properties, demonstrated by reducing the
level of C-reactive protein that may play an important role in
chronic inflammatory diseases, such as rheumatoid arthritis—a
chronic condition that is a major cause of disability. Some small
studies have suggested a modest effect of statins in decreasing
disease activity in patients with rheumatoid arthritis, but a recent
larger study involving over 30,000 patients with rheumatoid
arthritis showed no beneficial effect. Furthermore, it has been
suggested that statins may have a role in the primary prevention
of rheumatoid arthritis, but so far there has been no solid
evidence base to support this hypothesis. Before statins can
potentially be included in the treatment options for rheumatoid
arthritis, or possibly prescribed for the prevention of this
condition, there needs to be a much stronger evidence base,
such as larger studies with longer follow-up periods, which
clearly demonstrates any significant clinical benefits of statin use.
Why Was This Study Done? This large study (more than
200,000 patients) with a long follow-up period (average of 10
years) was conducted to discover whether there was any
kind of association between persistent use of statins and the
onset of rheumatoid arthritis.
What Did the Researchers Do and Find? The researchers
conducted a retrospective cohort study among the members
of Maccabi Healthcare Services (a health maintenance
organization [HMO]) in Israel, which has 1.8-million
enrollees and covers every section of the Israeli population,
to identify statin users who were at least 18 years of age and
did not have RA or a related disease at study entry. The
cohort covered the period 1998–2007 and included
members who were continuously enrolled in the HMO
from 1995 to 1998. The researchers then analyzed the
incidence of newly diagnosed rheumatoid arthritis, recording
the date of first diagnostic codes (International Classification
of Diseases, 9th revision [ICD-9]) associated with rheumatoid
arthritis during the study follow-up period. To assess any
potential effects of ‘‘healthy adherer’’ bias (good adherence
to medication in patients with a chronic illness may be more
likely to lead to better health and improved survival), the
researchers also examined any possible association between
persistent statin use and the development of osteoarthritis, a
common degenerative joint disease that is unlikely to be
affected by statin use.
During the study follow-up period, there were 2,578 incident
cases of rheumatoid arthritis and 17,878 incident cases of
osteoarthritis. The crude incidence density rate of rheuma-
toid arthritis among patients who did not persistently take
statins was 51% higher than that of patients who used
statins for at least 80% of the follow-up period. Furthermore,
patients who persistently used statins had a risk ratio of 0.58
for rheumatoid arthritis compared with patients who did not
persistently use statins. In the osteoarthritis cohort analysis,
high persistence with statin use was associated with a
modest decrement in risk ratio (0.85) compared to patients
who did not persist with statins.
What Do These Findings Mean? This study suggests that
there is an association between persistence with statin
therapy and reduced risk of developing rheumatoid arthritis.
Although the researchers took into account the possibility of
healthy adherer bias (by comparing results with the
osteoarthritis cohort), this study has other limitations, such
as the retrospective design, and the nonrandomization of
statin use, which could affect the interpretation of the
results. However, the observed associations were greater
than those that would be expected from methodological
biases alone. Larger, systematic, controlled, prospective
studies with high efficacy statins, particularly in younger
adults who are at increased risk for rheumatoid arthritis, are
needed to confirm these findings and to clarify the exact
nature of the biological relationship between adherence to
statin therapy and the incidence of rheumatoid arthritis.
Additional Information. Please access these Web sites via
theonlineversionofthissummaryathttp://dx.doi.org/10.1371/
journal.pmed.1000336.
N Arthritis Research UK provides a wide range of information
on arthritis research
N The American College of Rheumatology provides informa-
tion on rheumatology research
N Patient information on rheumatoid arthritis is available at
Patient UK
N Extensive information about statins is available at statin
answers
Statins and Prevention of RA
PLoS Medicine | www.plosmedicine.org 13 September 2010 | Volume 7 | Issue 9 | e1000336